Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  General Electric Company    GE

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

General Electric Company : Omnyx Ships Sixth VL4 Digital Pathology Scanner

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/27/2011 | 04:05pm CEST

GE announced today the shipment of the Omnyx? VL4 scanner to beta customers worldwide. To date, six Omnyx VL4 scanners have been shipped and are in operation for testing purposes. This marks a significant milestone in Omnyx's efforts to deliver a leading Integrated Digital Pathology solution. The Omnyx solution will be demonstrated at the upcoming Pathology Visions conference in San Diego.

The Omnyx VL4 scanner was created through the joint venture of UPMC and GE Healthcare. It is designed to resolve the tradeoff between speed and image quality through its patented two camera technology. All scanning operations including tissue detection and focus are automated to minimize labor. It is tightly integrated to an enterprise software solution that enables high-speed digital viewing over standard networks and provides a complete digital workflow for research use for both the pathologist and histology personnel.

George Michalopolous, Chair of Pathology at UPMC, comments, "The recent shipment of the VL4 Scanner to UPMC allows us to further test the Omnyx technology and make progress with our digitization plans for our department. Whether you look at the software system or their scanning instruments, the Omnyx team has developed an integrated product that promises to advance pathology."

Feedback from the various beta testing sites is instrumental in preparing the products for commercial availability.

Dr. Sylvia Asa, Chair of Pathology at University Health Network said, "I have been impressed with the image quality of the VL4 and I have high expectations for the Omnyx product. The Omnyx images are the best I have seen. In addition, there were several instances when I favored the Omnyx digital image on the monitor over the glass slide in the microscope."

So far, University Health Network (UHN) in Toronto Canada has scanned and reviewed over 2,000 slides as part of its testing activities. The facility started with 5 pathologists and, within 7 weeks, had 22 pathologists from nine specialty areas testing the system. This demonstrates its intuitive ease of use and is a result of the system having been designed by pathologists, for pathologists. Dr. Andrew Evans will discuss UHN's preliminary experience with the Omnyx Integrated Digital Pathology solution and the VL4 scanner at the upcoming Pathology Visions tradeshow in San Diego.

Gene Cartwright, CEO of the Omnyx joint venture comments, "We are grateful and thankful for the support we are receiving from our beta sites. Great customers help us make a better product. There is no better way of making sure we have it right than working hand-in-hand with our customers. We expect the field of digital pathology will advance very quickly once a complete solution is made available. The shipment of the Omnyx VL4 scanner is a very important milestone toward that goal."

The Omnyx Integrated Digital Pathology solution is designed to integrate into a comprehensive platform what are often stand-alone products. It combines high speed, high quality whole slide scanning with scalable information technology products to create a solution that addresses the reliability and process requirements of pathologists and enables single and multi-site organizations to benefit from increased efficiencies and greater access to peers in the field. The Omnyx products are for research use only and not for diagnostic use.

The Omnyx product line will include scanners, workstations, algorithms, servers, and digital archives for storage.

By digitizing the slides and corresponding workflow, the Omnyx solution is intended to do what a traditional microscope cannot, and improve collaboration, communication and efficiency.

ABOUT OMNYX:

Omnyx, LLC, (www.omnyx.com) is a joint venture of GE Healthcare and UPMC (the University of Pittsburgh Medical Center) with locations in Pittsburgh, Pa. and Piscataway, N.J. The company is developing an Integrated Digital Pathology system to allow pathology departments worldwide to move to an all-digital workflow. Their products include a family of high speed whole-slide scanners and an enterprise software product enabling image management, workflow automation, image analysis algorithms and system integration. Close collaboration with pathologists at UPMC and other institutions along with their relationship with GE Healthcare allows Omnyx to focus its innovation on the needs of anatomic pathologists worldwide. Omnyx products are currently in development and are for research use only. They are not for use in diagnostic procedures.

ABOUT GE HEALTHCARE:

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com

GE Healthcare
Corey Miller, 414.469.5499
corey.miller@ge.com
OR
Omnyx
Tony Melanson, 857.272.1321
Tony.Melanson@omnyx.com


© Business Wire 2011
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GENERAL ELECTRIC COMPANY
08/18 GENERAL ELECTRIC : FG Concessions Narrow Gauge Railway Lines to GE
08/18 GENERAL ELECTRIC : MILITARY $25,956 Federal Contract Awarded to G.E. Aviation
08/18 GENERAL ELECTRIC : UNILAG students get soft skills training
08/17 GENERAL ELECTRIC : Patent Issued for Interleaved Soft Switching Boost Converter ..
08/17 GENERAL ELECTRIC : Patent Issued for Turbine Rotor and Blade Assembly with Multi..
08/17 EXCLUSIVE : SEC officials' holdings, legal work, pose potential conflicts
08/17 GENERAL ELECTRIC : GE's Jon Freedman Named to Board of Directors of the WateReus..
08/17 GENERAL ELECTRIC : GE’s Jon Freedman Named to Board of Directors of the Wa..
08/17 CURRENT, POWERED BY GE : Helps Home Depot Expand Rooftop Solar Energy to 30 East..
08/17 GENERAL ELECTRIC : MILITARY $28,904 Federal Contract Awarded to G.E. Aviation
More news
News from SeekingAlpha
06:07a Goodbye American Express, Hello Synchrony Financial
08/18 Top Gain Dow Dogs Are General Electric, IBM, & Pfizer Per Broker August Targe..
08/18 GE to supply turbines for Australia's largest wind farm
08/18 WALL STREET BREAKFAST : AT&T On The Brink Of A Mega Deal
08/18 Tracking David Winters' Wintergreen Advisers Portfolio - Q2 2017 Update
Financials ($)
Sales 2017 125 806 M
EBIT 2017 16 564 M
Net income 2017 12 050 M
Debt 2017 73 584 M
Yield 2017 3,78%
P/E ratio 2017 18,29
P/E ratio 2018 15,21
EV / Sales 2017 2,27x
EV / Sales 2018 1,98x
Capitalization 212 553 M
Chart GENERAL ELECTRIC COMPANY
Duration : Period :
General Electric Company Technical Analysis Chart | GE | US3696041033 | 4-Traders
Technical analysis trends GENERAL ELECTRIC COMPANY
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 29,3 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
John L. Flannery Chief Executive Officer & Director
Jeffrey R. Immelt Chairman
Daniel Janki Treasurer & Senior VP-Global Operations
Jeffrey S. Bornstein Vice Chairman & Chief Financial Officer
Jim Fowler Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
GENERAL ELECTRIC COMPANY-22.31%212 553
3M13.98%122 546
SIEMENS-4.71%111 600
HONEYWELL INTERNATIONAL17.26%103 323
DUPONT10.60%70 171
JARDINE STRATEGIC HOLDINGS LIMITED27.40%48 516